Genocea Appoints Dr. John E. Bishop as Senior Vice President of Pharmaceutical Sciences
May 23 2016 - 7:30AM
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical
company developing T cell-directed vaccines and immunotherapies,
today announced that John E. Bishop, Ph.D. has joined the company
as senior vice president of pharmaceutical sciences.
“I am delighted to welcome John to Genocea at such an exciting
time for the company as we progress GEN-003, our immunotherapy for
genital herpes, towards expected Phase 3 initiation next year and
continue to advance our research and preclinical programs in
immuno-oncology and infectious diseases,” said Chip Clark,
president and chief executive officer of Genocea. “John’s
experience in successfully building teams to support
pharmaceutical sciences and manufacturing activities for all stages
of product development and commercialization will be incredibly
valuable to Genocea.”
Dr. Bishop brings a wealth of experience in process development,
formulation, quality, and supply chain management across diverse
product platforms, ranging from small molecules to complex
proteins. Prior to joining Genocea, Dr. Bishop was senior vice
president of pharmaceutical sciences at Momenta Pharmaceuticals,
Inc., where he worked since 2004 and was responsible for all
aspects of chemistry, manufacturing, and controls across an array
of development and commercial-stage products. Prior to
Momenta, he spent a combined 13 years in various roles of
increasing responsibility at Millennium Pharmaceuticals, DuPont
Pharmaceuticals, and Alcon Laboratories. Dr. Bishop holds a
Ph.D. in Organic Chemistry from the University of California,
Berkeley, an M.B.A. from Northeastern University, and a B.S. in
Chemistry and German from Tufts University.
About Genocea Genocea is harnessing the power
of T cell immunity to develop life-changing vaccines and
immunotherapies. T cells are increasingly recognized as a critical
element of protective immune responses to a wide range of diseases,
but traditional discovery methods have proven unable to identify
the targets of such protective immune response. Using ATLAS, its
proprietary technology platform, Genocea identifies these targets
to potentially enable the rapid development of medicines to address
critical patient needs. Genocea's pipeline of novel clinical stage
T cell-enabled product candidates includes GEN-003 for genital
herpes, GEN-004 for the prevention of infection by all serotypes of
pneumococcus (development suspended pending further data analysis
and consultation with our advisers), and earlier-stage programs in
chlamydia, genital herpes prophylaxis, malaria and cancer
immunotherapy. For more information, please visit the company's
website at www.genocea.com.
For media:
Liz Bryan
Spectrum Science Communications
O: 202-587-2526
lbryan@spectrumscience.com
For investors:
Jonathan Poole
Genocea Biosciences, Inc.
O: 617-876-8191
jonathan.poole@genocea.com
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Apr 2024 to May 2024
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From May 2023 to May 2024